Followers | 443 |
Posts | 63457 |
Boards Moderated | 1 |
Alias Born | 04/26/2007 |
Friday, July 17, 2015 6:31:48 PM
The cost savings to the institutions are significant. Anywhere from 50% to 70% cost savings opportunity. When you are factoring in a $600 to $900 saving per patient undergoing PCI, there are hospitals and health systems that could save 10's of thousands to 100's of thousands of dollars on the hospital level...Millions of dollars on the large system level.
High dose AGGRASTAT may offer additional safety benefits over REOPRO and INTEGRILIN in patients undergoing PCI, as well as equivalent efficacy data...No large trials to directly compare these agents, but enough data in the literature to formulate a solid hypothesis...
MERCK screwed up years ago. They didn't listen to the key clinical trialists....
Which means...Great for anyone invested in Medicure at this point...
Also, with MDCO's anti-platelet option coming out at a higher price point, you may see an up-tic in GP IIb/IIIa inhibition utilization.
Rub-A-Dub-Dub…Three perps in a tub…The broker, the banker, and the counterfeit equity maker!!!
Please research all stocks before investing. My posts are my opinions and are not buy or sell recommendations.
Recent MCUJF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/05/2023 10:02:35 PM
- Medicure reiterates its commitment to providing exceptional access to its branded pitavastatin (zypitamag) to people living with hiv • InvestorsHub NewsWire • 08/30/2023 11:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM